CAMBRIDGE, Mass., Aug. 28, 2013 /PRNewswire/ -- Flagship
Ventures, a leading venture capital and venture creation firm
focused on healthcare and sustainability, today congratulates four
of its portfolio companies, Agios Pharmaceuticals, BIND
Therapeutics, Oasys Water and Selecta Biosciences for being
recognized as World Economic Forum Technology Pioneers for
2014.
Agios, BIND, Oasys and Selecta are among the 36 most innovative
technology startups selected this year by the World Economic Forum
for their potential to transform the future of business and
society. Flagship portfolio companies Joule and LS9 were previously
recognized as World Economic Forum Technology Pioneers in 2012 and
2008, respectively.
"It is a great honor to see four companies, in which Flagship
has been a founding investor, simultaneously recognized for their
diverse accomplishments," said Noubar
Afeyan, Managing Partner and Chief Executive Officer of
Flagship Ventures. "We are fully committed to developing and
financing startup companies based on pioneering innovations that
can transform the healthcare and sustainability industries. We
congratulate Agios, BIND, Oasys and Selecta for being recognized on
this global stage and are looking forward to their continued
success."
Each year the World Economic Forum chooses a select number of
Technology Pioneers from hundreds of applicants. Candidate
companies are nominated by Members, constituents and collaborators
of the World Economic Forum, and by the public. A selection
committee, comprised of top technology and innovation experts,
academics and venture capitalists, reviews all applications before
making its recommendation to the World Economic Forum.
More information about the World Economic Forum's Technology
Pioneers program can be found at
http://www.weforum.org/techpioneers.
About Flagship Ventures
Realizing entrepreneurial innovation is the mission of Flagship
Ventures. The firm operates through two synergistic units:
VentureLabs™ which invents and launches transformative companies,
and Venture Capital, which finances and develops innovative,
early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures
manages over $900 million in capital.
The Flagship team is active in three principal business sectors:
therapeutics, health technologies and sustainability/clean
technology. Past successful Flagship portfolio companies include:
Accuri Cytometers (acquired by Becton, Dickinson and Company),
Adnexus (acquired by Bristol-Myers Squibb), Hypnion (acquired by
Eli Lilly), Agios (NASDAQ: AGIO), AVEO (NASDAQ: AVEO), BG Medicine
(NASDAQ: BGMD), Receptos (NASDAQ: RCPT), Tetraphase (NASDAQ: TTPH),
and Morphotek (acquired by Eisai). Additional notable portfolio
companies include: Affinnova, BIND Therapeutics, Joule Unlimited,
Quanterix, and Moderna Therapeutics. For more information, please
visit www.flagshipventures.com.
Contact:
For Flagship Ventures: Rachel Brenner
Ruder Finn
212.715.1623
flagship@ruderfinn.com
SOURCE Flagship Ventures